Short answer
Dexcom (DXCM) filed an 8-K current report with the SEC on February 26, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Board expanded to 12 directors; Rick Osterloh appointed immediately, term through 2026 Annual Meeting.
Dexcom 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Board expanded to 12 directors; Rick Osterloh appointed immediately, term through 2026 Annual Meeting
- Osterloh designated independent; assigned to Compensation Committee and Technology Committee
- Initial RSU grant valued at $500,000, vesting annually over 3 years
- Pro-rata annual RSU grant of ~$101,027 at 2026 Annual Meeting (base annual award $325,000)
- All non-employee director equity accelerates fully upon change in control
Item 7.01 · Regulation FD Disclosure
- Rick Osterloh appointed to Dexcom Board of Directors, effective February 26, 2026
- Board composition change signals potential strategic direction; Osterloh's background (hardware/consumer tech at Google) relevant to Dexcom's wearable CGM business
- Full details in press release Exhibit 99.1
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Dexcom 8-K filings
Get the next DXCM 8-K as it lands
Follow DXCM for push alerts, or ask the research agent what this filing means.